Viral Specific T Cell Therapy for COVID-19 Related Pneumonia

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 18, 2020

Primary Completion Date

September 20, 2024

Study Completion Date

September 20, 2024

Conditions

Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmSymptomatic COVID-19 Infection Laboratory-Confirmed

Interventions

BIOLOGICAL

SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes

Given IV

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER

NCT04742595 - Viral Specific T Cell Therapy for COVID-19 Related Pneumonia | Biotech Hunter | Biotech Hunter